iBio (IBIO) Common Equity (2011 - 2026)

iBio (IBIO) has 16 years of Common Equity data on file, last reported at $77.5 million in Q1 2026.

• On a quarterly basis, Common Equity rose 581.28% year-over-year to $77.5 million in Q1 2026; TTM through Mar 2026 was $77.5 million, a 581.28% increase from a year earlier, with the FY2025 full-year figure at $14.9 million, down 30.22% from the prior year.
• Common Equity for Q1 2026 stood at $77.5 million, up from $56.6 million in the prior quarter.
• Over the last five years, Common Equity for IBIO reached as high as $79.4 million in Q1 2022 and fell as low as $9.2 million in Q4 2023.
• Historically, Common Equity has averaged $32.9 million across 5 years, with a median of $18.8 million in 2022.
• Across the five-year window, Common Equity slumped 79.22% in 2022 and soared 581.28% in 2026, its largest moves.
• Year by year, Common Equity stood at $18.8 million in 2022, then plunged by 51.14% to $9.2 million in 2023, then soared by 51.08% to $13.9 million in 2024, then jumped by 307.05% to $56.6 million in 2025, then jumped by 37.09% to $77.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $77.5 million in Q1 2026, $56.6 million in Q4 2025, and $56.0 million in Q3 2025.